| Title | Combination of immuno-MS and ELISA: a new strategy for detection of cancer |
| Authors | Sun, Yunbo Hou, Liping Song, Chunyan Han, Zhiguo Huang, Yajuan Fu, Haiyuan Zhou, Xiaoming Yuan, Jian Yang, Baoan Sun, Li Wei, Kaihua Qian, Xiaohong Liu, Shuchen |
| Affiliation | Beijing Inst Radiat Med, 27 Taiping Rd, Beijing 100850, Peoples R China. Beijing Proteome Res Ctr, 33 Life Sci Pk Road, Beijing 102206, Peoples R China. State Key Lab Prote, 33 Life Sci Pk Rd, Beijing 102206, Peoples R China. Beijing C&N Int Sci Tech Co Ltd, 33 Life Sci Pk Rd, Beijing 102206, Peoples R China. Peking Univ, Canc Hosp, Dept Pathol, Beijing 100850, Peoples R China. Wuhu 2 Peoples Hosp, Wuhu 241000, Anhui Province, Peoples R China. Cent S Univ, Changhsa 410000, Hunan Province, Peoples R China. Beijing Inst Radiat Med, 27 Taiping Rd, Beijing 100850, Peoples R China. Wei, KH Qian, XH (reprint author), State Key Lab Prote, Beijing Proteome Res Ctr, Beijing Inst Radiat Med, 33 Life Sci Pk Rd, Beijing 102206, Peoples R China. |
| Keywords | pep5 liver cancer combination detection HK MOLECULAR-WEIGHT KININOGEN HEPATOCELLULAR-CARCINOMA OVARIAN-CANCER SERUM MARKERS DOMAIN 5 IN-VIVO SYSTEM ACTIVATION BIOMARKER STAGE |
| Issue Date | 2016 |
| Publisher | INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY |
| Citation | INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY.2016,9,(2),1168-1176. |
| Abstract | Objective: Currently, detection method for cancer mainly includes biopsy, ultrasound and blood-based biomarkers detection. Although all of these methods are being employed in the clinical practice, they are often characterized by low sensitivity or/and specificity. In this study, we took the liver cancer as an example and combined immuno-MS and ELISA to verify the potential biomarker role of pep5 for hepatocellular carcinoma detection. Methods: A polypeptide named pep5 was designed and its antibody was used to detect liver cancer by methods of immuno-MS and ELISA. Proteins were determined using immunoprecipitation and Immunohistochemistry. Result: The data showed that combination of immuno-MS and ELISA can largely improve the sensitivity and specificity of the cancer detection. While the sensitivity and specificity are 74.83% and 71.52% (immuno-MS alone), 67.72% and 97.35% (ELISA alone), the combination of immuno-MS and ELISA can lead to a sensitivity and specificity of 72.78% and 100%, respectively. Immuno-MS and ELISA assay showed that pep5 antibody binds with both pep5 and its precursor protein. Conclusion: The combination of immuno-MS and ELISA may be a new strategy of the detection of cancer, and the pep5 also can be a hopeful serum biomarker for liver cancer. |
| URI | http://hdl.handle.net/20.500.11897/438902 |
| ISSN | 1936-2625 |
| Indexed | SCI(E) |
| Appears in Collections: | 北京肿瘤医院 |
